Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Magn Reson Med. 2018 Mar 9;80(5):2040–2052. doi: 10.1002/mrm.27163

Figure 4.

Figure 4

WIN-TIFP versus MRI-TIFPD based on the fluid-mechanical model for U251 tumor groups; control, bevacizumab, and Cilengitide+RT. All groups showed significant positive correlations.